Guest guest Posted January 23, 2011 Report Share Posted January 23, 2011 And here we are... for anyone who has not treated and is genotype 1... no Interferon. On Sun, Jan 23, 2011 at 4:42 PM, Christ <ludichrist2000@...> wrote: Bavituximab to Star in Phase II Hepatitis C Trial Peregrine Pharmaceuticals, Inc. has started a Phase II clinical trial to determine if bavituximab plus ribavirin elicits an early virologic response in people with previously untreated genotype-1 Hepatitis C. Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis C Open-Label Trial Evaluating 12 Weeks of Therapy With Novel Targeted Antibody Bavituximab in Combination With Ribavirin Versus Standard of Care TUSTIN, CA--(Marketwire - January 10, 2011) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a randomized Phase II clinical trial in patients with previously untreated genotype-1 hepatitis C virus (HCV) infection. This open-label trial will determine the early virologic response (EVR) rate of patients after 12 weeks of therapy with Peregrine's bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody with immune-modulating potential, in combination with the antiviral drug ribavirin versus standard of care, pegylated interferon alpha 2a and ribavirin. Peregrine expects to complete enrollment shortly in an ongoing Phase Ib HCV trial and report data by mid-year. Continue reading this entire article:http://www.marketwire.com/press-release/Peregrine-Initiates-Randomized-Phase-II-Trial-of-Bavituximab-in-Chronic-Hepatitis-C-NASDAQ-PPHM-1377628.htm http://www.hepatitis-central.com/mt/archives/2011/01/bavituximab_to.html Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 23, 2011 Report Share Posted January 23, 2011 Ribavirin is a bitch on it's own Don but not near as bad as the Interferon... ask your doctor..... OMG this Bears game is gonna give me a heart attack.On Sun, Jan 23, 2011 at 4:58 PM, Christ <ludichrist2000@...> wrote: Hummmmm....a possibility for me? Maybe......but will the trial come here? Maybe my doctor can get me in the door. Next question - how bad will this med kick my butt? mull mull mull Bavituximab to Star in Phase II Hepatitis C Trial Peregrine Pharmaceuticals, Inc. has started a Phase II clinical trial to determine if bavituximab plus ribavirin elicits an early virologic response in people with previously untreated genotype-1 Hepatitis C. Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis C Open-Label Trial Evaluating 12 Weeks of Therapy With Novel Targeted Antibody Bavituximab in Combination With Ribavirin Versus Standard of Care TUSTIN, CA--(Marketwire - January 10, 2011) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a randomized Phase II clinical trial in patients with previously untreated genotype-1 hepatitis C virus (HCV) infection. This open-label trial will determine the early virologic response (EVR) rate of patients after 12 weeks of therapy with Peregrine's bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody with immune-modulating potential, in combination with the antiviral drug ribavirin versus standard of care, pegylated interferon alpha 2a and ribavirin. Peregrine expects to complete enrollment shortly in an ongoing Phase Ib HCV trial and report data by mid-year. Continue reading this entire article:http://www.marketwire.com/press-release/Peregrine-Initiates-Randomized-Phase-II-Trial-of-Bavituximab-in-Chronic-Hepatitis-C-NASDAQ-PPHM-1377628.htm http://www.hepatitis-central.com/mt/archives/2011/01/bavituximab_to.html Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 23, 2011 Report Share Posted January 23, 2011 ribavirin is an evil drug, but interferon is the devil!On Jan 23, 2011, at 1:02 PM, Theresa Gottlieb wrote: Ribavirin is a bitch on it's own Don but not near as bad as the Interferon... ask your doctor..... OMG this Bears game is gonna give me a heart attack.On Sun, Jan 23, 2011 at 4:58 PM, Christ <ludichrist2000@...> wrote: Hummmmm....a possibility for me? Maybe......but will the trial come here? Maybe my doctor can get me in the door. Next question - how bad will this med kick my butt? mull mull mull Bavituximab to Star in Phase II Hepatitis C Trial Peregrine Pharmaceuticals, Inc. has started a Phase II clinical trial to determine if bavituximab plus ribavirin elicits an early virologic response in people with previously untreated genotype-1 Hepatitis C. Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis C Open-Label Trial Evaluating 12 Weeks of Therapy With Novel Targeted Antibody Bavituximab in Combination With Ribavirin Versus Standard of Care TUSTIN, CA--(Marketwire - January 10, 2011) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a randomized Phase II clinical trial in patients with previously untreated genotype-1 hepatitis C virus (HCV) infection. This open-label trial will determine the early virologic response (EVR) rate of patients after 12 weeks of therapy with Peregrine's bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody with immune-modulating potential, in combination with the antiviral drug ribavirin versus standard of care, pegylated interferon alpha 2a and ribavirin. Peregrine expects to complete enrollment shortly in an ongoing Phase Ib HCV trial and report data by mid-year. Continue reading this entire article:http://www.marketwire.com/press-release/Peregrine-Initiates-Randomized-Phase-II-Trial-of-Bavituximab-in-Chronic-Hepatitis-C-NASDAQ-PPHM-1377628.htm http://www.hepatitis-central.com/mt/archives/2011/01/bavituximab_to.html Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 23, 2011 Report Share Posted January 23, 2011 A bear once tried to have a game with me. I had on a big blue military Pea Coat. I opened it up so that I suddenly looked 4 times bigger than I really was. That bear decided to turn left, and haul ass. Then I woke up. I never smoked that stuff again. LOL :-) Bavituximab to Star in Phase II Hepatitis C Trial Peregrine Pharmaceuticals, Inc. has started a Phase II clinical trial to determine if bavituximab plus ribavirin elicits an early virologic response in people with previously untreated genotype-1 Hepatitis C. Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis C Open-Label Trial Evaluating 12 Weeks of Therapy With Novel Targeted Antibody Bavituximab in Combination With Ribavirin Versus Standard of Care TUSTIN, CA--(Marketwire - January 10, 2011) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a randomized Phase II clinical trial in patients with previously untreated genotype-1 hepatitis C virus (HCV) infection. This open-label trial will determine the early virologic response (EVR) rate of patients after 12 weeks of therapy with Peregrine's bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody with immune-modulating potential, in combination with the antiviral drug ribavirin versus standard of care, pegylated interferon alpha 2a and ribavirin. Peregrine expects to complete enrollment shortly in an ongoing Phase Ib HCV trial and report data by mid-year. Continue reading this entire article:http://www.marketwire.com/press-release/Peregrine-Initiates-Randomized-Phase-II-Trial-of-Bavituximab-in-Chronic-Hepatitis-C-NASDAQ-PPHM-1377628.htm http://www.hepatitis-central.com/mt/archives/2011/01/bavituximab_to.html Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 23, 2011 Report Share Posted January 23, 2011 Also, I hope all of you took note that in this Phase II is still only for treatment naive people. At this time ny, that leaves you out. However, it's usually in a Phase III test those of us that had failed a previous tx.However, you have to look and see how long this has been in study. Like I've said before, if any of these new drugs actually make it to a Phase II, you are still looking at probably another 5 years. From the time that I first heard about the protease inhibitors, it was 7 years just as I surmised. Honestly, I thought that I would not be treated again until this year anyway. I am sooo grateful for the clinical; because, I may have not made it through the wait.Gloria Amen to thatOn Sun, Jan 23, 2011 at 5:03 PM, Barrett <barrjohnm@...> wrote: ribavirin is an evil drug, but interferon is the devil!On Jan 23, 2011, at 1:02 PM, Theresa Gottlieb wrote: Ribavirin is a bitch on it's own Don but not near as bad as the Interferon... ask your doctor..... OMG this Bears game is gonna give me a heart attack.On Sun, Jan 23, 2011 at 4:58 PM, Christ <ludichrist2000@...> wrote: Hummmmm....a possibility for me? Maybe......but will the trial come here? Maybe my doctor can get me in the door. Next question - how bad will this med kick my butt? mull mull mull Bavituximab to Star in Phase II Hepatitis C Trial Peregrine Pharmaceuticals, Inc. has started a Phase II clinical trial to determine if bavituximab plus ribavirin elicits an early virologic response in people with previously untreated genotype-1 Hepatitis C. Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis C Open-Label Trial Evaluating 12 Weeks of Therapy With Novel Targeted Antibody Bavituximab in Combination With Ribavirin Versus Standard of Care TUSTIN, CA--(Marketwire - January 10, 2011) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a randomized Phase II clinical trial in patients with previously untreated genotype-1 hepatitis C virus (HCV) infection. This open-label trial will determine the early virologic response (EVR) rate of patients after 12 weeks of therapy with Peregrine's bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody with immune-modulating potential, in combination with the antiviral drug ribavirin versus standard of care, pegylated interferon alpha 2a and ribavirin. Peregrine expects to complete enrollment shortly in an ongoing Phase Ib HCV trial and report data by mid-year. Continue reading this entire article:http://www.marketwire.com/press-release/Peregrine-Initiates-Randomized-Phase-II-Trial-of-Bavituximab-in-Chronic-Hepatitis-C-NASDAQ-PPHM-1377628.htm http://www.hepatitis-central.com/mt/archives/2011/01/bavituximab_to.html Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 23, 2011 Report Share Posted January 23, 2011 Hi Gloria,thanks I did not know that it was phase 3 for people who need to treat a second time. Maybe that is why the clinical trials I see are for people who have treated before, I guess they are phase 1 or 2.On Jan 23, 2011, at 1:55 PM, Gloria wrote: Also, I hope all of you took note that in this Phase II is still only for treatment naive people. At this time ny, that leaves you out. However, it's usually in a Phase III test those of us that had failed a previous tx.However, you have to look and see how long this has been in study. Like I've said before, if any of these new drugs actually make it to a Phase II, you are still looking at probably another 5 years. From the time that I first heard about the protease inhibitors, it was 7 years just as I surmised. Honestly, I thought that I would not be treated again until this year anyway. I am sooo grateful for the clinical; because, I may have not made it through the wait.Gloria Amen to thatOn Sun, Jan 23, 2011 at 5:03 PM, Barrett <barrjohnm@...> wrote: ribavirin is an evil drug, but interferon is the devil!On Jan 23, 2011, at 1:02 PM, Theresa Gottlieb wrote: Ribavirin is a bitch on it's own Don but not near as bad as the Interferon... ask your doctor..... OMG this Bears game is gonna give me a heart attack.On Sun, Jan 23, 2011 at 4:58 PM, Christ <ludichrist2000@...> wrote: Hummmmm....a possibility for me? Maybe......but will the trial come here? Maybe my doctor can get me in the door. Next question - how bad will this med kick my butt? mull mull mull Bavituximab to Star in Phase II Hepatitis C Trial Peregrine Pharmaceuticals, Inc. has started a Phase II clinical trial to determine if bavituximab plus ribavirin elicits an early virologic response in people with previously untreated genotype-1 Hepatitis C. Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis C Open-Label Trial Evaluating 12 Weeks of Therapy With Novel Targeted Antibody Bavituximab in Combination With Ribavirin Versus Standard of Care TUSTIN, CA--(Marketwire - January 10, 2011) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a randomized Phase II clinical trial in patients with previously untreated genotype-1 hepatitis C virus (HCV) infection. This open-label trial will determine the early virologic response (EVR) rate of patients after 12 weeks of therapy with Peregrine's bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody with immune-modulating potential, in combination with the antiviral drug ribavirin versus standard of care, pegylated interferon alpha 2a and ribavirin. Peregrine expects to complete enrollment shortly in an ongoing Phase Ib HCV trial and report data by mid-year. Continue reading this entire article:http://www.marketwire.com/press-release/Peregrine-Initiates-Randomized-Phase-II-Trial-of-Bavituximab-in-Chronic-Hepatitis-C-NASDAQ-PPHM-1377628.htm http://www.hepatitis-central.com/mt/archives/2011/01/bavituximab_to.html Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 23, 2011 Report Share Posted January 23, 2011 nyIt's the other way around! Treatment naive (never had tx before) are excepted in especially the Phase II's. I think that Phase I is for folks that are really out there as guinea pigs. In fact, I think that the clinical that you were on was probably one of those. I think I remember you saying that they closed the whole trial down??Actually, it is pretty harsh for anyone that has already failed a tx, to go and try it again, even if it is a trial. In my case, I feel very honoured and besides it worked. So, they try out these new meds almost before any of us are going to hear about them. By Phase III, they are ready to try it out on folks that did not respond the 1st time. I think that I read somewhere that there was only 695 people in the world that were selected for the trial I was on. That was for someone who initially responded to the standard care and then failed sometime after the 12 weeks. Hi Gloria,thanks I did not know that it was phase 3 for people who need to treat a second time. Maybe that is why the clinical trials I see are for people who have treated before, I guess they are phase 1 or 2.On Jan 23, 2011, at 1:55 PM, Gloria wrote: Also, I hope all of you took note that in this Phase II is still only for treatment naive people. At this time ny, that leaves you out. However, it's usually in a Phase III test those of us that had failed a previous tx.However, you have to look and see how long this has been in study. Like I've said before, if any of these new drugs actually make it to a Phase II, you are still looking at probably another 5 years. From the time that I first heard about the protease inhibitors, it was 7 years just as I surmised. Honestly, I thought that I would not be treated again until this year anyway. I am sooo grateful for the clinical; because, I may have not made it through the wait.Gloria Amen to thatOn Sun, Jan 23, 2011 at 5:03 PM, Barrett <barrjohnm@...> wrote: ribavirin is an evil drug, but interferon is the devil!On Jan 23, 2011, at 1:02 PM, Theresa Gottlieb wrote: Ribavirin is a bitch on it's own Don but not near as bad as the Interferon... ask your doctor..... OMG this Bears game is gonna give me a heart attack.On Sun, Jan 23, 2011 at 4:58 PM, Christ <ludichrist2000@...> wrote: Hummmmm....a possibility for me? Maybe......but will the trial come here? Maybe my doctor can get me in the door. Next question - how bad will this med kick my butt? mull mull mull Bavituximab to Star in Phase II Hepatitis C Trial Peregrine Pharmaceuticals, Inc. has started a Phase II clinical trial to determine if bavituximab plus ribavirin elicits an early virologic response in people with previously untreated genotype-1 Hepatitis C. Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis C Open-Label Trial Evaluating 12 Weeks of Therapy With Novel Targeted Antibody Bavituximab in Combination With Ribavirin Versus Standard of Care TUSTIN, CA--(Marketwire - January 10, 2011) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a randomized Phase II clinical trial in patients with previously untreated genotype-1 hepatitis C virus (HCV) infection. This open-label trial will determine the early virologic response (EVR) rate of patients after 12 weeks of therapy with Peregrine's bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody with immune-modulating potential, in combination with the antiviral drug ribavirin versus standard of care, pegylated interferon alpha 2a and ribavirin. Peregrine expects to complete enrollment shortly in an ongoing Phase Ib HCV trial and report data by mid-year. Continue reading this entire article:http://www.marketwire.com/press-release/Peregrine-Initiates-Randomized-Phase-II-Trial-of-Bavituximab-in-Chronic-Hepatitis-C-NASDAQ-PPHM-1377628.htm http://www.hepatitis-central.com/mt/archives/2011/01/bavituximab_to.html Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 23, 2011 Report Share Posted January 23, 2011 I'm not sure I'd want to be on a Phase 1 trial of ANY TYPE. That is guinea pig stuff... On Sun, Jan 23, 2011 at 9:01 PM, Gloria <gadamscan@...> wrote: nyIt's the other way around! Treatment naive (never had tx before) are excepted in especially the Phase II's. I think that Phase I is for folks that are really out there as guinea pigs. In fact, I think that the clinical that you were on was probably one of those. I think I remember you saying that they closed the whole trial down?? Actually, it is pretty harsh for anyone that has already failed a tx, to go and try it again, even if it is a trial. In my case, I feel very honoured and besides it worked. So, they try out these new meds almost before any of us are going to hear about them. By Phase III, they are ready to try it out on folks that did not respond the 1st time. I think that I read somewhere that there was only 695 people in the world that were selected for the trial I was on. That was for someone who initially responded to the standard care and then failed sometime after the 12 weeks. Hi Gloria,thanks I did not know that it was phase 3 for people who need to treat a second time. Maybe that is why the clinical trials I see are for people who have treated before, I guess they are phase 1 or 2. On Jan 23, 2011, at 1:55 PM, Gloria wrote: Also, I hope all of you took note that in this Phase II is still only for treatment naive people. At this time ny, that leaves you out. However, it's usually in a Phase III test those of us that had failed a previous tx. However, you have to look and see how long this has been in study. Like I've said before, if any of these new drugs actually make it to a Phase II, you are still looking at probably another 5 years. From the time that I first heard about the protease inhibitors, it was 7 years just as I surmised. Honestly, I thought that I would not be treated again until this year anyway. I am sooo grateful for the clinical; because, I may have not made it through the wait.Gloria Amen to thatOn Sun, Jan 23, 2011 at 5:03 PM, Barrett <barrjohnm@...> wrote: ribavirin is an evil drug, but interferon is the devil!On Jan 23, 2011, at 1:02 PM, Theresa Gottlieb wrote: Ribavirin is a bitch on it's own Don but not near as bad as the Interferon... ask your doctor..... OMG this Bears game is gonna give me a heart attack.On Sun, Jan 23, 2011 at 4:58 PM, Christ <ludichrist2000@...> wrote: Hummmmm....a possibility for me? Maybe......but will the trial come here? Maybe my doctor can get me in the door. Next question - how bad will this med kick my butt? mull mull mull Bavituximab to Star in Phase II Hepatitis C Trial Peregrine Pharmaceuticals, Inc. has started a Phase II clinical trial to determine if bavituximab plus ribavirin elicits an early virologic response in people with previously untreated genotype-1 Hepatitis C. Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis C Open-Label Trial Evaluating 12 Weeks of Therapy With Novel Targeted Antibody Bavituximab in Combination With Ribavirin Versus Standard of Care TUSTIN, CA--(Marketwire - January 10, 2011) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a randomized Phase II clinical trial in patients with previously untreated genotype-1 hepatitis C virus (HCV) infection. This open-label trial will determine the early virologic response (EVR) rate of patients after 12 weeks of therapy with Peregrine's bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody with immune-modulating potential, in combination with the antiviral drug ribavirin versus standard of care, pegylated interferon alpha 2a and ribavirin. Peregrine expects to complete enrollment shortly in an ongoing Phase Ib HCV trial and report data by mid-year. Continue reading this entire article:http://www.marketwire.com/press-release/Peregrine-Initiates-Randomized-Phase-II-Trial-of-Bavituximab-in-Chronic-Hepatitis-C-NASDAQ-PPHM-1377628.htm http://www.hepatitis-central.com/mt/archives/2011/01/bavituximab_to.html Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.